Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
606 articles with Merck KGaA, Darmstadt, Germany
-
EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
2/23/2023
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile, consistent with what was seen earlier in the double-blind period (DBP) of the clinical trials.
-
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
2/13/2023
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.
-
AI/ML applications are being deployed at large pharmaceutical companies, but in order to truly maximize their potential, better infrastructure is needed. AION Labs believes it is answering that call.
-
Community Financial Institutions: A Corporate Partner in Community Development
1/27/2023
Community financial institutions are essential in promoting economic and social justice in underserved communities.
-
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
1/3/2023
PDS Biotechnology Corporation announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241, which will join the pipeline as PDS0301.
-
Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
12/22/2022
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets.
-
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
12/22/2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets.
-
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
12/6/2022
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the "Breez™".
-
Merck KGaA, Darmstadt, Germany Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster
11/21/2022
Company aims to launch one new product or indication every 1.5 years on average, bolstered by external innovation.
-
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing Capacity
11/16/2022
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA.
-
Seven pharma CEOs announce new joint action to accelerate net zero healthcare
11/3/2022
CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
-
Merck KGaA, Darmstadt, Germany and p-Chip Corporation Collaborate to Improve Trust and Transparency in Machine-to-Machine Driven Industrial Value Chains
11/3/2022
Merck KGaA, Darmstadt, Germany announced the conclusion of a joint development agreement to develop and implement a new solution that offers never-before-seen levels of digital trust in machine-to-machine -connected industrial value chains.
-
Gerresheimer and Merck KGaA, Darmstadt, Germany, Transform Primary Packaging into Digital Twins
10/27/2022
Gerresheimer AG and Merck KGaA, Darmstadt, Germany jointly developed a digital twin solution to further ensure traceability and trust in crucial steps along the pharmaceutical supply chain.
-
EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
10/26/2022
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced findings which demonstrated that annualized relapse rates remained low and Expanded Disability Status Scale scores were stable in people with relapsing multiple sclerosis treated with investigational evobrutinib through more than three and half years.
-
EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care
10/26/2022
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the company will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held October 26-28, 2022 in Amsterdam, the Netherlands.
-
Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round.
-
BIOCORP and Merck KGaA, Darmstadt, Germany, Sign a New Partnership for Smart Drug Delivery
10/10/2022
BIOCORP and Merck KGaA, Darmstadt, Germany, will collaborate on the development and global distribution of a specific version of Mallya for drug delivery devices BIOCORP and Merck KGaA, Darmstadt, Germany, are extending their collaboration after an already ongoing program BIOCORP will receive payments for the development and additional revenues from sales after launch following the completion of certain milestones.
-
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
10/4/2022
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector has opened a commercial facility for its new Millipore® CTDMO Services offering at the company's site in Martillac, France.
-
Merck KGaA, Darmstadt, Germany, Partners with CNote to Invest $20 Million in Under-resourced Communities
10/4/2022
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced it made a $ 20 million commitment to CNote, a women-led impact investment platform.
-
Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
9/21/2022
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.